Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acetazolamide

FDA-approved product (tablet, oral), marketed as Acetazolamide, Diamox, Acetazolamide Sodium.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Acetazolamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Altitude sickness
  • Angle-closure glaucoma
  • Congestive heart failure
  • Edema
  • Epilepsy
  • Glaucoma
  • Heart failure
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA14.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli17.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae10.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis85.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 6 of 6 lab records
Open Acetazolamide in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acetazolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Idiopathic Intracranial Hypertension: Prognostic Factors and Multidisciplinary Management

    NCT07707544 · start 2026-06-01

    Registered record
    Registry ID
    NCT07707544
    Conditions
    Idiopathic Intracranial Hypertension
    Interventions
    lumbo-peritoneal shunt; Conservative Management: Centered on lifestyle modifications for weight reduction, alongside targeted medical therapies including carbonic anhydrase inhibitors (e.g., acetazolamide) and/or topiramate.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2026-06-01
    Completion
    2026-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Intracranial Hypertension
    Interventionlumbo-peritoneal shunt; Conservative Management: Centered on lifestyle modifications for weight reduction, alongside targeted medical therapies including carbonic anhydrase inhibitors (e.g., acetazolamide) and/or topiramate.
    PhaseNot applicable
    Registry statusActive not recruiting

  • Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

    NCT07482072 · start 2026-03

    Registered record
    Registry ID
    NCT07482072
    Conditions
    Alzheimer Dementia (AD); Diabete Type 2
    Interventions
    [18F]FDG PET; [11C]PIB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-03
    Completion
    2026-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Dementia (AD); Diabete Type 2
    Intervention[18F]FDG PET; [11C]PIB
    PhaseNot recorded
    Registry statusRecruiting

  • Add-on Diuretics in Acute Decompensated Heart Failure

    NCT07372040 · start 2026-02-01

    Registered record
    Registry ID
    NCT07372040
    Conditions
    Acute Decompensated Heart Failure
    Interventions
    empagliflozin; Acetazolamide; metolazone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2027-02-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Decompensated Heart Failure
    Interventionempagliflozin; Acetazolamide; metolazone
    PhasePhase 2
    Registry statusRecruiting

  • Preoperative Acetazolamide

    NCT07101250 · start 2025-10-30

    Registered record
    Registry ID
    NCT07101250
    Conditions
    Post Operative Pain; Laparoscopic Hysterectomy; Referred Pain
    Interventions
    Acetazolamide 500 MG Extended Release Oral Capsule; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-10-30
    Completion
    2026-11-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Operative Pain; Laparoscopic Hysterectomy; Referred Pain
    InterventionAcetazolamide 500 MG Extended Release Oral Capsule; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning

    NCT03806751 · start 2025-02-01

    Registered record
    Registry ID
    NCT03806751
    Conditions
    Validation of a New Noninvasive Method to Obtain the Arterial Input Function (AIF) Directly by PET Imaging
    Interventions
    [O-15]Water; Acetazolamide
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2025-02-01
    Completion
    2027-02-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionValidation of a New Noninvasive Method to Obtain the Arterial Input Function (AIF) Directly by PET Imaging
    Intervention[O-15]Water; Acetazolamide
    PhaseEarly phase 1
    Registry statusWithdrawn

  • Test of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion

    NCT06624267 · start 2024-11

    Registered record
    Registry ID
    NCT06624267
    Conditions
    Microvascular Disease; Microvascular Complications; Diabetes Mellitus Type 2; Cerebral Hypoperfusion; Dementia
    Interventions
    PET
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-11
    Completion
    2027-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMicrovascular Disease; Microvascular Complications; Diabetes Mellitus Type 2; Cerebral Hypoperfusion +1 more
    InterventionPET
    PhaseNot recorded
    Registry statusNot yet recruiting

  • HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men

    NCT06498505 · start 2024-07-15

    Registered record
    Registry ID
    NCT06498505
    Conditions
    High Altitude
    Interventions
    Acetazolamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-07-15
    Completion
    2025-08-31
    Enrolment
    303

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Altitude
    InterventionAcetazolamide; Placebo
    PhasePhase 4
    Registry statusCompleted

  • HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men

    NCT06499727 · start 2024-07-15

    Registered record
    Registry ID
    NCT06499727
    Conditions
    Acute Mountain Sickness
    Interventions
    Acetazolamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-07-15
    Completion
    2025-08-31
    Enrolment
    303

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Mountain Sickness
    InterventionAcetazolamide; Placebo
    PhasePhase 4
    Registry statusCompleted

  • HighCycle Study: Acetazolamide, High Altitude and Plasma Volume

    NCT07118462 · start 2024-07-15

    Registered record
    Registry ID
    NCT07118462
    Conditions
    High Altitude Effects; High Altitude Hypoxia; Acute Mountain Sickness (AMS); Plasma Volume; Women
    Interventions
    Acetazolamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-07-15
    Completion
    2025-12-31
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Altitude Effects; High Altitude Hypoxia; Acute Mountain Sickness (AMS); Plasma Volume +1 more
    InterventionAcetazolamide; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment

    NCT06913712 · start 2024-06-27

    Registered record
    Registry ID
    NCT06913712
    Conditions
    Idiopathic Intracranial Hypertension (IIH)
    Interventions
    Weight loss without pharmacotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-06-27
    Completion
    2028-05-01
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Intracranial Hypertension (IIH)
    InterventionWeight loss without pharmacotherapy
    PhaseNot recorded
    Registry statusRecruiting

  • RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

    NCT06146101 · start 2024-05-02

    Registered record
    Registry ID
    NCT06146101
    Conditions
    Obstructive Sleep Apnea
    Interventions
    IHL-42X Low Dose; IHL-42X High Dose; Placebo; IHL-42X (Optimal Dose); Dronabinol; Acetazolamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2024-05-02
    Completion
    2025-07-27
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionIHL-42X Low Dose; IHL-42X High Dose; Placebo; IHL-42X (Optimal Dose) +3 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Acetazolamide or Metolazone in Acute Heart Failure

    NCT06273397 · start 2024-05-01

    Registered record
    Registry ID
    NCT06273397
    Conditions
    Heart Failure Acute; Decompensated Heart Failure
    Interventions
    Acetazolamide 250 MG; Metolazone 2.5 MG; Furosemide Injection
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2024-05-01
    Completion
    2027-05-01
    Enrolment
    1,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure Acute; Decompensated Heart Failure
    InterventionAcetazolamide 250 MG; Metolazone 2.5 MG; Furosemide Injection
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption

    NCT06110078 · start 2024-01-18

    Registered record
    Registry ID
    NCT06110078
    Conditions
    Obesity
    Interventions
    Acetazolamide
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2024-01-18
    Completion
    2024-05-01
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionAcetazolamide
    PhaseEarly phase 1
    Registry statusUnknown

  • Cerebral Vascular Reserve in Small Vessel Disease and Alzheimers Disease

    NCT05443308 · start 2022-06-21

    Registered record
    Registry ID
    NCT05443308
    Conditions
    Alzheimer Disease; Dementia, Vascular
    Interventions
    Cerebral [15O]H2O PET before and after diamox infusion
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-06-21
    Completion
    2023-04-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Dementia, Vascular
    InterventionCerebral [15O]H2O PET before and after diamox infusion
    PhaseNot recorded
    Registry statusUnknown

  • Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide

    NCT05023941 · start 2021-12-01

    Registered record
    Registry ID
    NCT05023941
    Conditions
    Acute Mountain Sickness
    Interventions
    Acetazolamide; Doctormate® (twice daily for 6 days); Doctormate® (forth daily for 3 days)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-12-01
    Completion
    2022-08-30
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Mountain Sickness
    InterventionAcetazolamide; Doctormate® (twice daily for 6 days); Doctormate® (forth daily for 3 days)
    PhasePhase 4
    Registry statusCompleted